Programmed cell death 1
Jump to navigation
Jump to search
Programmed cell death 1, abbreviated PDCD1 and PD1,[1] is a protein (and gene) with an important role in immune system regulation and cancer. It is found on T lymphocytes.
It is also known as CD279.
PD1 binds with programmed death-ligand 1 (dealt with separately) and programmed death-ligand 2.[2]
Background
Cytotoxic T cell function is regulated by receptor pairs found on the tumour and lymphocyte:[2]
| Function | Tumour cell | T cell |
|---|---|---|
| Antigen presentation | MHC | TCR |
| Signal inhibition | PD-1 | PD-L1 (CD274), PD-L2 (CD273) |
Drugs
- Pembrolizumab.
- Nivolumab.
- Atezolizumab.
- Durvalumab.
- Avelumab.
Uncertain whether it binds PD-1:
- Pidilizumab.
IHC
- There is no standard antibody.
- Currently, each drug company has its own clone. Whether the antibodies are interchangeable is a subject of study.
| Clone | IHC platform | Associated drug | Testing required |
|---|---|---|---|
| 28-8 | Dako | Nivolumab[3] | no testing for squamous carcinoma, pending further information for non-squamous |
| 22C3 | Dako | Pembrolizumab[4] | testing required |
| SP142 | Ventana | Atezolizumab[5] | testing required |
| SP263 | Ventana | Durvalumab | testing likely required |
See also
- Programmed death-ligand 1 (PD-L1).
References
- ↑ Online 'Mendelian Inheritance in Man' (OMIM) 600244
- ↑ 2.0 2.1 Ribas, A. (Jun 2012). "Tumor immunotherapy directed at PD-1.". N Engl J Med 366 (26): 2517-9. doi:10.1056/NEJMe1205943. PMID 22658126.
- ↑ Borghaei, H.; Paz-Ares, L.; Horn, L.; Spigel, DR.; Steins, M.; Ready, NE.; Chow, LQ.; Vokes, EE. et al. (Oct 2015). "Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.". N Engl J Med 373 (17): 1627-39. doi:10.1056/NEJMoa1507643. PMID 26412456.
- ↑ Garon, EB.; Rizvi, NA.; Hui, R.; Leighl, N.; Balmanoukian, AS.; Eder, JP.; Patnaik, A.; Aggarwal, C. et al. (May 2015). "Pembrolizumab for the treatment of non-small-cell lung cancer.". N Engl J Med 372 (21): 2018-28. doi:10.1056/NEJMoa1501824. PMID 25891174.
- ↑ Fehrenbacher, L.; Spira, A.; Ballinger, M.; Kowanetz, M.; Vansteenkiste, J.; Mazieres, J.; Park, K.; Smith, D. et al. (Apr 2016). "Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.". Lancet 387 (10030): 1837-46. doi:10.1016/S0140-6736(16)00587-0. PMID 26970723.